Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

Adaptor Proteins, Signal Transducing / metabolism Animals Apoptosis Cell Cycle Proteins / metabolism Cell Line, Tumor Cell Proliferation Cell Survival Cellular Senescence Drug Resistance, Neoplasm ErbB Receptors / metabolism Female Gene Deletion Gene Expression Regulation, Neoplastic Humans Lung Neoplasms / metabolism MAP Kinase Kinase 1 / metabolism Male Mice Mice, Knockout Mutation Signal Transduction Transcription Factors / metabolism Transcription, Genetic YAP-Signaling Proteins
YAP dormancy drug resistance drug tolerance epidermal growth factor receptor lung cancer senescence

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
13 01 2020
Historique:
received: 17 05 2019
revised: 11 10 2019
accepted: 10 12 2019
entrez: 15 1 2020
pubmed: 15 1 2020
medline: 4 8 2020
Statut: ppublish

Résumé

Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Blockade of ERK1/2 reactivation following EGFR TKI treatment by combined EGFR/MEK inhibition uncovers cells that survive by entering a senescence-like dormant state characterized by high YAP/TEAD activity. YAP/TEAD engage the epithelial-to-mesenchymal transition transcription factor SLUG to directly repress pro-apoptotic BMF, limiting drug-induced apoptosis. Pharmacological co-inhibition of YAP and TEAD, or genetic deletion of YAP1, all deplete dormant cells by enhancing EGFR/MEK inhibition-induced apoptosis. Enhancing the initial efficacy of targeted therapies could ultimately lead to prolonged treatment responses in cancer patients.

Identifiants

DOI: 10.1016/j.ccell.2019.12.006 PMID: 31935369 PMC: PMC7146079
pubmed: 31935369
pii: S1535-6108(19)30576-8
doi: 10.1016/j.ccell.2019.12.006
pmc: PMC7146079
mid: NIHMS1569353
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Cell Cycle Proteins 0
Transcription Factors 0
YAP-Signaling Proteins 0
YAP1 protein, human 0
Yap1 protein, mouse 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
MAP Kinase Kinase 1 EC 2.7.12.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104-122.e12

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL105373
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA154303
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA222218
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA220497
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233800
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA135257
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
BMC Bioinformatics. 2018 Apr 12;19(1):135
pubmed: 29649993
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Oncogene. 2008 Oct 9;27(46):5975-87
pubmed: 18711403
J Am Soc Mass Spectrom. 1998 Mar;9(3):225-33
pubmed: 9879360
Nat Protoc. 2009;4(12):1798-806
pubmed: 20010931
Bioinformatics. 2015 Jun 15;31(12):1913-9
pubmed: 25638815
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Cancer Discov. 2016 Dec;6(12):1334-1341
pubmed: 27694386
Cancer Cell. 2017 Aug 14;32(2):221-237.e13
pubmed: 28781121
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Anal Chem. 2016 Dec 20;88(24):12248-12254
pubmed: 28193034
J Biol Chem. 2009 May 15;284(20):13355-62
pubmed: 19324877
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Cell Rep. 2018 Oct 30;25(5):1304-1317.e5
pubmed: 30380420
Nat Commun. 2016 Feb 15;7:10498
pubmed: 26876920
Cell. 2014 Jul 3;158(1):185-197
pubmed: 24954535
Cell. 2011 Nov 11;147(4):759-72
pubmed: 22078877
Cancer Res. 2008 Apr 15;68(8):2789-94
pubmed: 18413746
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Cell. 2014 Jul 3;158(1):171-84
pubmed: 24954536
Nature. 2011 Jun 08;474(7350):179-83
pubmed: 21654799
Proteomics. 2017 Aug;17(15-16):
pubmed: 28686798
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Nature. 2009 Dec 24;462(7276):1070-4
pubmed: 20033049
EMBO J. 2004 Feb 25;23(4):790-9
pubmed: 14765127
Nat Med. 2015 May;21(5):440-8
pubmed: 25849130
Cell Death Differ. 2005 Aug;12(8):1008-14
pubmed: 15947788
J Thorac Oncol. 2017 Oct;12(10):1588-1594
pubmed: 28751247
Oncogene. 2013 Aug 15;32(33):3922
pubmed: 23160371
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40
pubmed: 17667954
Cell Rep. 2015 Apr 14;11(2):270-82
pubmed: 25843714
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Cell Chem Biol. 2019 Mar 21;26(3):378-389.e13
pubmed: 30581134
Cell. 2012 Dec 21;151(7):1457-73
pubmed: 23245941
Proteomes. 2017 Aug 01;5(3):
pubmed: 28763045
Curr Protoc Mol Biol. 2015 Jan 05;109:21.29.1-21.29.9
pubmed: 25559105
Cell Rep. 2013 Dec 26;5(6):1611-24
pubmed: 24332857
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Nat Cell Biol. 2014 Jan;16(1):108-17
pubmed: 24362629
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cell Rep. 2015 Oct 20;13(3):524-532
pubmed: 26456820
Chem Biol. 2013 Feb 21;20(2):146-59
pubmed: 23438744
Physiol Rev. 2014 Oct;94(4):1287-312
pubmed: 25287865
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Genes Dev. 2008 Jul 15;22(14):1962-71
pubmed: 18579750
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Nat Biotechnol. 2016 Mar;34(3):339-44
pubmed: 26789497
Eur Respir Rev. 2014 Sep;23(133):356-66
pubmed: 25176972
BMC Bioinformatics. 2016 Oct 3;17(1):404
pubmed: 27716038
Cancer Cell. 2016 Jun 13;29(6):783-803
pubmed: 27300434
J Natl Cancer Inst. 2010 Oct 20;102(20):1536-46
pubmed: 20858887
Nat Med. 2016 Mar;22(3):262-9
pubmed: 26828195
Nat Cell Biol. 2016 Sep;18(9):917-29
pubmed: 27479603
Mol Cell Biol. 2008 Apr;28(7):2426-36
pubmed: 18227151
Clin Cancer Res. 2013 Jan 1;19(1):279-90
pubmed: 23091115
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
Nat Genet. 2015 Mar;47(3):250-6
pubmed: 25665005
J Clin Oncol. 2008 Feb 1;26(4):626-32
pubmed: 18235122
Eur J Med Chem. 2017 Sep 29;138:96-114
pubmed: 28651155
Nat Chem Biol. 2016 Apr;12(4):282-9
pubmed: 26900866
Oncotarget. 2016 Aug 9;7(32):51922-51933
pubmed: 27409162
Mol Cell. 2005 Feb 18;17(4):525-35
pubmed: 15721256
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
Nat Methods. 2017 Oct;14(10):959-962
pubmed: 28846090
Lancet Oncol. 2012 Nov;13(11):e470-81
pubmed: 23117002
Mol Cell. 2016 Mar 3;61(5):695-704
pubmed: 26942674
PLoS Med. 2007 Oct;4(10):1681-89; discussion 1690
pubmed: 17973573
Cell. 2003 Jun 13;113(6):703-16
pubmed: 12809602
Structure. 2016 Jan 5;24(1):179-186
pubmed: 26724994
Cancer Discov. 2015 Sep;5(9):960-971
pubmed: 26036643
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Cancer Discov. 2012 Oct;2(10):934-47
pubmed: 22961667
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376152
PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680
pubmed: 17973572
Structure. 2015 Nov 3;23(11):2076-86
pubmed: 26592798
PLoS Med. 2007 Oct 9;4(10):e294
pubmed: 17927446

Auteurs

Kari J Kurppa (KJ)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Yao Liu (Y)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.

Ciric To (C)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Tinghu Zhang (T)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.

Mengyang Fan (M)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.

Amir Vajdi (A)

Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Erik H Knelson (EH)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Yingtian Xie (Y)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Klothilda Lim (K)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Paloma Cejas (P)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Andrew Portell (A)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Patrick H Lizotte (PH)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Scott B Ficarro (SB)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.

Shuai Li (S)

Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.

Ting Chen (T)

Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.

Heidi M Haikala (HM)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Haiyun Wang (H)

School of Life Science and Technology, Tongji University, 200092 Shanghai, China.

Magda Bahcall (M)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Yang Gao (Y)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA.

Sophia Shalhout (S)

Stem Cell Program, Boston Children's Hospital, Boston, MA 02215, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.

Steffen Boettcher (S)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Bo Hee Shin (BH)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Tran Thai (T)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Margaret K Wilkens (MK)

Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA.

Michelle L Tillgren (ML)

Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA.

Mierzhati Mushajiang (M)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Man Xu (M)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Jihyun Choi (J)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Arrien A Bertram (AA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Benjamin L Ebert (BL)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Rameen Beroukhim (R)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

Pratiti Bandopadhayay (P)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02115, USA.

Mark M Awad (MM)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Prafulla C Gokhale (PC)

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA.

Paul T Kirschmeier (PT)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Jarrod A Marto (JA)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.

Fernando D Camargo (FD)

Stem Cell Program, Boston Children's Hospital, Boston, MA 02215, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.

Rizwan Haq (R)

Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Department of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Cloud P Paweletz (CP)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Kwok-Kin Wong (KK)

Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.

David A Barbie (DA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.

Henry W Long (HW)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Nathanael S Gray (NS)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.

Pasi A Jänne (PA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, LC4114, Boston, MA 02215, USA. Electronic address: pasi_janne@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Eucaryotes › Animaux › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cycle cellulaire › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Vieillissement › Vieillissement de la cellule › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Délétion de séquence › Délétion de gène › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Mitogen-Activated Protein Kinase Kinases › MAP Kinase Kinase 1 › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › Transcription génétique › Treatment-Induced Tumor Dormancy through...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Protéines de signalisation YAP › Treatment-Induced Tumor Dormancy through...